Makale detayı · 2018
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
YÖKSİS
OpenAlex
SJR Q1
JCR Q1
Atıf 947
Üst %1
Yüzdelik 100.0%
FWCI 64.68
- Yıl
- 2018
- Tür
- article
Veri kaynağı ayrımı
- YÖKSİS YÖKSİS makale kaydı
- YÖKSİS dergi adı The Lancet
- Katalog eşleşmesi (ISSN) The Lancet
- OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)
Özet
Özet henüz derlenmedi; DergiPark / OpenAlex kuyruğu işlenince burada görünecek.
Konular
Atıflar
OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.
947 atıf
OpenAlex cited_by_count (önbellek / veritabanı)
Yerel katalogda bu makaleye atıf yapan 11 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).
- Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis 2025
- Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial 2020
- Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis 2020
- Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis 2021
- Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis 2021
- Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60 2024
- Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis 2023
- Effects of disease-modifying therapies on remyelination in multiple sclerosis; evaluation via visual evoked potential test 2024
- Effects of disease-modifying therapies on remyelination in multiple sclerosis; evaluation via visual evoked potential test 2024
- Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five‐year clinical outcomes 2023